Boardroom Alpha
Boardroom Alpha
BYSI · Current Report (Form 8-K) · Filed December 15, 2025

Beyondspring Inc — Current Report (Form 8-K)

Form
8-K
Filed
December 15, 2025
Period
Dec 15, 2025
Ticker
BYSI
Accession
0001171843-25-007943
Boardroom Alpha · Filing insights

BeyondSpring signs agreements to sell 8,333,637 SEED Therapeutics Series A-1 preferred shares for $35.4 million; second closings expected 1H 2026.

About Beyondspring Inc
Market cap
$26M
1Y TSR
−59.0%
3Y TSR
−4.8%
Board grade
C-
Sector
Healthcare
CEO
Min Qiu
Last annual meeting: Oct 13, 2026 · View full Beyondspring Inc profile →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

                                     

FORM 8-K

                                     

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 15, 2025 (December 15, 2025)

                                     

BeyondSpring Inc.

(Exact name of registrant as specified in its charter)

                                     

 

Cayman Islands 001-38024 Not Applicable
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

100 Campus Drive, West Side, 4th Floor, Suite 410

Florham Park, New Jersey

07932
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: +1 (646) 305-6387

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share BYSI The NASDAQ Stock Market LLC

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01. Other Events.

 

As previously disclosed, on January 24, 2025, BeyondSpring Inc. (the “Company”) entered into a Preferred Share Purchase Agreement (each, “Purchase Agreement” and collectively, the “Purchase Agreements”) with each of Winning View Investment Limited (as amended by the First Amendment to Purchase Agreement, dated February 17, 2025, between the Company and Winning View Investment Limited.), FULL TECH CORPORATE DEVELOPMENT LIMITED, and Mapfil Investment Limited to sell an aggregate of 8,333,637 Series A-1 Preferred Shares (the “Shares”) of SEED Therapeutics Inc., for an aggregate purchase price of approximately $35.4 million, or $4.25 per share.

 

Pursuant to the terms and subject to the conditions set forth in each Purchase Agreement, Winning View Investment Limited had agreed to purchase from the Company 1,436,327 Shares no later than December 15, 2025; (2) FULL TECH CORPORATE DEVELOPMENT LIMITED had agreed to purchase from the Company 555,576 Shares no later than December 15, 2025; and (3) Mapfil Investment Limited had agreed to purchase from the Company 1,111,152 Shares no later than December 15, 2025 (the foregoing clauses (1)-(3), collectively, the “Second Closings”). The Second Closings are currently expected to be completed in the first half of 2026, but there can be no assurance that the Second Closings will not be further delayed or as to the exact timing of the Second Closings.

 

The foregoing description of the Purchase Agreements and the transactions contemplated thereby do not purport to be complete and are qualified in their entirety by reference to the Purchase Agreements, copies of which were filed as Exhibits 10.1, 10.2 and 10.3, respectively, to the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on January 28, 2025, and as Exhibit 10.4 to the Current Report on Form 8-K filed with the SEC on February 25, 2025.

 

Cautionary Statement Concerning Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this Current Report on Form 8-K include, but are not limited to, statements regarding: the timing of the consummation of the proposed transactions; the Company’s anticipated progress, business plans, business strategy and clinical trials; and other statements that are not historical fact. These statements are based on the Company’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: delays in or the inability to satisfy the conditions to complete the potential transactions; the inability to recognize the anticipated benefits of the potential transactions; business disruption during the pendency of or following the potential transactions; the effects of macroeconomic conditions, including any geopolitical instability and actual or perceived changes in interest rates and economic inflation; and other risks, including those described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025. Forward-looking statements contained in this Current Report on Form 8-K are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 15, 2025

 

  BeyondSpring Inc.
     
     
  By: /s/ Lan Huang
  Name: Lan Huang
  Title: Chairperson and Chief Executive Officer

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Beyondspring Inc (BYSI)

Reference

Frequently asked questions

When did Beyondspring Inc file this 8-K?
Beyondspring Inc (BYSI) filed this Current Report (Form 8-K) with the SEC on December 15, 2025. The accession number assigned by EDGAR is 0001171843-25-007943.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
BeyondSpring signs agreements to sell 8,333,637 SEED Therapeutics Series A-1 preferred shares for $35.4 million; second closings expected 1H 2026. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Beyondspring Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Beyondspring Inc has filed under CIK 1677940, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer